ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases.
Who We Are Our vision
Our vision is to become the world’s leading biotechnology company with innovative platforms and pipelines.
Core Platform
Bispecific antibody platform. Our core values are life-improvement, collaboration, innovation and novel therapy.
A bispecific antibody platform with robust penetrative ability through the blood-brain-barrier (BBB) as a treatment to various neurodegenerative diseases
The Grabody B platform targets insulin-like growth factor 1 receptor (IGF1R) to function as a BBB shuttle
IMMUNO-ONCOLOGY
IMMUNO-ONCOLOGY
Bispecific antibody to address current limitations of PD-(L)1 checkpoint inhibitors
Minimize the systemic toxicity associated with 4-1BB based immunotherapy, increase low reponse rates and overcome the resistance observed with traditional PD-(L)1 therapy
ADC
ADC
Developing antibody drug conjugates (ADC) with an improved therapy index
Challenging the development of rare blood cancer treatments with ADC drug candidates that have better in vivo pharmacokinetic parameters
